Myriad to go ahead with business split
This article was originally published in Clinica
Executive Summary
Myriad Genetics has received the green light from its board of directors to proceed with the planned spin-off of its research and drug development units. The move is expected to maximise the potential of Myriad's core's molecular diagnostics business, which has seen its revenues growing steadily over the last several quarters. This business will operate as Myriad Genetics, and trade under the new ticker symbol MGX. It will have 800 employees and five marketed diagnostics products – BRACAnalysis, Colaris, Colaris AP, Melaris and theraGuide 5-FU. The separate pharma and research businesses will operate under the name Myriad Pharmaceuticals, and take on the existing ticker symbol MYGN. It will have around 200 employees and focus on forging research partnerships and the development of drugs to treat cancer and infectious diseases. Salt Lake City, Utah-based Myriad first made public its intention to split its pharmaceutical and diagnostic units in September.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.